Marker Therapeutics, Inc. — Director's Dealing 2012

Apr 24, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2012-02-17

Reporting Person: WILSON GLYNN (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-17	Common Stock	J	166667	$0.15	Acquired	1213726	Direct

Footnotes

F1: These shares were issued in lieu of $25,000 worth of debt.